Low-dose S-ketamine in Women With Prenatal Depression

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

Prenatal depression is an important risk factor of postpartum depression. Low-dose ketamine has been used for depression treatment. As a stereoisomer of ketamine, s-ketamine has similar effects to ketamine in anti-depression. We speculate that, for pregnant women with prenatal depression, low-dose s-ketamine infusion after childbirth may reduce the incidence of postpartum depression.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Collaborators: Beijing Tiantan Hospital; Huaian Maternal and Child Health Care Hospital; Hunan Provincial Maternal and Child Health Care Hospital; Nanjing Maternal and Child Health Care Hospital; Peking University International Hospital
• Treatments: Esketamine; Ketamine

Criteria

Inclusion Criteria:

1. Maternal age ≥18 years;

2. Prenatal Edinburgh postnatal depression scale score ≥10 points.

Exclusion Criteria:

1. A clear history of mental illness (depression, schizophrenia, etc.) or communication difficulties;

2. Severe pregnancy complications, such as severe preeclampsia, placental implantation, HELLP (syndrome hemolytic anemia, elevated liver function and low platelet count) syndrom, placenta previa, and placental abruption;

3. American Society of Anesthesiologists classification ≥III;

4. Presence of contraindications to ketamine/s-ketamine use, such as refractory hypertension, severe cardiovascular disease (New York Heart Association classification ≥III), and hyperthyroidism.